Previous close | 1.5400 |
Open | 1.6000 |
Bid | 1.6000 x 100 |
Ask | 1.7000 x 100 |
Day's range | 1.5400 - 1.7500 |
52-week range | 0.5200 - 1.8700 |
Volume | |
Avg. volume | 138,149 |
Market cap | 59.254M |
Beta (5Y monthly) | 1.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3100 |
Earnings date | 03 May 2024 - 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.00 |
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]